At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
In Brief
A Phase 3 clinical trial evaluating Ranibizumab, Triamcinolone Acetonide, and 2 other interventions for Proliferative Diabetic Retinopathy and Diabetic Macular Edema. Completed, enrolled 333 participants across 56 sites.
Detailed Summary
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment. At the present time, it is not known whether intravitreal steroid or anti-vascular endothelial growth factor (anti-VEGF) injections are beneficial in preventing vision loss after panretinal photocoagulation (PRP) treatment. It is possible that one or both of the types of injections will prevent vision loss after PRP treatment. However, it is not known whether the benefits of the injections will outweigh the risks. It is possible that because of side effects, the injections may not be as good as laser alone in treating the diabetic retinopathy.
Study Details
Timeline
Interventions
Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
Sham injection at baseline and 4 weeks
Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.